Efficacy of postoperative intraperitoneal hyperthermic perfusion chemotherapy with oxaliplatin+5-Fluorouracil in the treatment of gastric cancer patients with peritoneal carcinomatosis

被引:0
|
作者
Yan, Kangpeng [1 ]
Wu, Kun [1 ]
Yan, Lan [2 ]
Liang, Lei [3 ]
Yuan, Yujun [4 ]
机构
[1] Jiangxi Canc Hosp, Abdominal Surg Oncol Ward 1, 159 Beijing East Rd, Nanchang 330029, Jiangxi, Peoples R China
[2] Jiangxi Canc Hosp, Dept Radiol, Nanchang, Jiangxi, Peoples R China
[3] Tangshan Peoples Hosp, Dept Gastroenter Surg, Tangshan, Peoples R China
[4] Quannan Peoples Hosp Jiangxi Prov, Dept Gen Surg, Ganzhou, Peoples R China
来源
JOURNAL OF BUON | 2019年 / 24卷 / 04期
关键词
gastric cancer; peritoneal carcinomatosis; oxaliplatin; 5-fluorouracil; intraperitoneal hyperthermic perfusion chemotherapy; CYTOREDUCTIVE SURGERY; SURVIVAL; TUMORS; HIPEC;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the effect of palliative laparoscopic resection of gastric cancer combined with intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with oxaliplatin + 5-fluorouracil (5-FU) on gastric cancer patients with peritoneal carcinomatosis (PC). Methods: 90 patients definitely diagnosed with gastric adenocarcinoma and PC and admitted to our hospital from March 2013 to March 2016 were collected and divided into IHPC group (n=45) and control group (n=45). In IHPC group, IHPC with oxaliplatin + 5-FU was carried out for the first time on the first day after operation, and then it was conducted once every other day for a total of 4 times. The clinical efficacy, quality of life, adverse reactions, postoperative tumor recurrence and survival of the patients were observed and recorded. Results: The total effective rates in IHPC group and control group were 62.2% (28/45) and 55.6% (25/45), respectively (p>0.05). In both groups, the curative effect was the best in moderately differentiated adenocarcinoma and worst in signet ring cell carcinoma. Besides, the effective rates of Karnofsky performance status (KPS) in the two groups after operation were 82.2% (37/45) and 75.6% (34/45), respectively (p=0.606). However, the renal function indexes, serum creatinine (sCr) and blood urea nitrogen (BUN) in the two groups of patients after operation were increased, and those in the IHPC group were higher than those in the control group (p=0.016, p=0.010). Moreover, follow-up results of patients' survival revealed that the OS and PFS in the IHPC group were significantly higher than those in the control group (p=0.041, p=0.045). Conclusions: Palliative laparoscopic resection of gastric cancer combined with IHPC with oxaliplatin + 5-FU has a definite therapeutic effect on gastric cancer with PC, which can achieve a better short-term clinical therapeutic effect and better postoperative quality of life
引用
收藏
页码:1587 / 1594
页数:8
相关论文
共 50 条
  • [21] Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin for Peritoneal Carcinomatosis Arising From Colorectal Cancer
    Gervais, Mai-Kim
    Dube, Pierre
    McConnell, Yarrow
    Drolet, Pierre
    Mitchell, Andrew
    Sideris, Lucas
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (07) : 438 - 443
  • [22] Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure
    de Jong, Loek A. W.
    Elekonawo, Fortune M. K.
    de Reuver, Philip R.
    Bremers, Andre J. A.
    de Wilt, Johannes H. W.
    Jansman, Frank G. A.
    ter Heine, Rob
    van Erp, Nielka P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (01) : 47 - 58
  • [23] Therapeutic value of intraperitoneal hyperthermic peritoneal perfusion for patients with gastric cancer
    Ikeguchi, M
    Maeta, M
    Kaibara, N
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1997, 11 (05) : 1081 - 1085
  • [24] Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Overview and rationale
    Roviello, F.
    Caruso, S.
    Neri, A.
    Marrelli, D.
    EJSO, 2013, 39 (12): : 1309 - 1316
  • [25] Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of digestive and peritoneal origin : Rationale
    Liberale, G.
    Pocard, M.
    Manganas, D.
    Ducreux, M.
    Lasser, P.
    Elias, D.
    ACTA CHIRURGICA BELGICA, 2006, 106 (03) : 291 - 296
  • [26] ASO Author Reflections: Neoadjuvant Oxaliplatin Therapy for Peritoneal Carcinomatosis, Any Impact on Subsequent Hyperthermic Intraperitoneal Chemotherapy Perfusion?
    Mangieri, Christopher W.
    Levine, Edward A.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 2494 - 2495
  • [27] ASO Author Reflections: Neoadjuvant Oxaliplatin Therapy for Peritoneal Carcinomatosis, Any Impact on Subsequent Hyperthermic Intraperitoneal Chemotherapy Perfusion?
    Christopher W. Mangieri
    Edward A. Levine
    Annals of Surgical Oncology, 2023, 30 : 2494 - 2495
  • [28] Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal Intraoperative chemotherapy for peritoneal carcinomatosis
    Capone, A.
    Valle, M.
    Proietti, F.
    Federici, O.
    Garofalo, A.
    Petrosillo, N.
    JOURNAL OF SURGICAL ONCOLOGY, 2007, 96 (06) : 507 - 513
  • [29] Reply to "Peritoneal carcinomatosis in patients with gastric cancer and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy"
    Graziosi, Luigina
    Marino, Eliabetta
    Donini, Annibale
    AMERICAN JOURNAL OF SURGERY, 2014, 208 (01): : 158 - 159
  • [30] Risk factors for peritoneal carcinomatosis in gastric cancer patients, and outcomes following resection and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kim, Ki Won
    Chow, Oliver
    Parikh, Kunal
    Blank, Sima
    Jibara, Ghalib
    Labow, Daniel M.
    Hiotis, Spiros P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)